evalu
serolog
respons
middl
east
respiratori
syndrom
coronaviru
merscov
infect
patient
accord
sever
group
asymptomat
infect
group
symptomat
infect
without
pneumonia
group
pneumonia
without
respiratori
failur
group
pneumonia
progress
respiratori
failur
group
none
group
patient
show
seroconvers
seroconvers
rate
gradual
increas
increas
diseas
sever
group
respect
p
group
patient
show
delay
increment
antibodi
titer
fourth
week
group
patient
show
robust
increment
antibodi
titer
third
week
among
patient
pneumonia
deceas
patient
show
seroconvers
third
week
surviv
patient
seroconvert
p
sinc
first
report
case
middl
east
respiratori
syndrom
coronaviru
merscov
zaki
et
al
small
larg
outbreak
occur
result
merscov
infect
relat
death
date
understand
fatal
respiratori
viral
infect
sever
serolog
investig
conduct
corman
et
al
min
et
al
park
et
al
payn
et
al
howev
practic
analysi
serodiagnost
paramet
clinic
usag
limit
previou
studi
due
insuffici
sampl
size
clinic
inform
manag
merscovinfect
patient
largest
number
patient
singl
center
korean
mer
outbreak
total
patient
identifi
kim
et
al
park
et
al
report
merscovinfect
patient
experienc
distinct
clinic
cours
rang
asymptomat
infect
sever
pneumonia
requir
mechan
ventil
base
find
evalu
serolog
respons
merscovinfect
patient
accord
diseas
sever
investig
potenti
role
serodiagnost
paramet
prognost
marker
among
merscovinfect
patient
admit
samsung
medic
center
tertiari
care
univers
hospit
korean
mer
outbreak
obtain
sera
patient
merscov
infect
confirm
diagnost
microbiolog
infecti
diseas
basi
realtim
revers
transcriptas
polymeras
chain
reaction
rrtpcr
assay
target
upstream
e
gene
upe
openread
frame
gene
corman
et
al
madani
epidemiolog
investig
data
electron
medic
record
review
obtain
exact
exposur
date
symptom
onset
clinic
cours
outcom
data
patient
one
residu
serum
sampl
per
week
ill
use
serolog
test
hospit
period
followup
serum
sampl
obtain
outpati
clinic
also
test
month
symptom
onset
institut
review
board
samsung
medic
center
approv
present
studi
clinic
cours
merscovinfect
patient
assess
week
symptom
onset
patient
divid
diseas
sever
group
asymptomat
infect
group
symptomat
infect
without
pneumonia
group
pneumonia
without
respiratori
failur
group
pneumonia
progress
respiratori
failur
group
practic
purpos
respiratori
failur
defin
need
mechan
ventil
patient
group
experienc
fatal
outcom
interv
symptom
onset
death
day
median
proport
underli
immunocompromis
condit
includ
diabet
solid
cancer
hematolog
malign
differ
group
distinct
clinic
present
sever
group
present
supplementari
fig
supplementari
tabl
addit
previou
report
seroconvers
statu
determin
base
neutral
activ
none
serum
sampl
merscovinfect
patient
necessarili
includ
sera
obtain
third
week
ill
show
neutral
activ
patient
consid
neg
seroconvers
none
serum
sampl
obtain
end
third
week
ill
show
neutral
activ
sampl
avail
neutral
test
thereaft
patient
consid
indetermin
respons
ie
interpret
applic
serum
show
neutral
activ
patient
consid
posit
seroconvers
patient
indetermin
respons
exclud
calcul
seroconvers
rate
definit
base
premis
patient
previou
exposur
merscov
first
mer
outbreak
korea
nonendem
countri
outbreak
merscov
exposur
date
symptom
onset
clearli
identifi
patient
owe
thorough
contact
investig
monitor
expos
individu
park
et
al
mersrel
symptom
includ
fever
myalgia
cough
sputum
diarrhea
provid
common
point
refer
use
day
post
onset
ill
dpoi
evalu
merscovinfect
patient
asymptomat
patient
day
diagnosi
merscov
infect
consid
day
symptom
onset
antimerscov
elisa
igg
iga
euroimmun
germani
base
solubl
merscov
spike
protein
domain
express
cell
muller
et
al
muth
et
al
raj
et
al
sera
test
accord
manufactur
instruct
dilut
secondari
detect
done
peroxidaselabel
antihuman
igg
iga
cutoff
valu
od
ratio
elisa
igg
elisa
iga
appli
present
studi
valu
exhibit
optim
perform
predict
neutral
activ
antimerscov
ifa
igm
euroimmun
perform
slide
carri
vero
cell
infect
full
merscov
corman
et
al
meyer
et
al
muller
et
al
muller
et
al
sera
test
accord
manufactur
instruct
dilut
weekli
posit
ifa
intens
consid
cutoff
intens
valu
ifa
igm
exhibit
optim
perform
predict
neutral
activ
merscov
prnt
perform
previous
describ
muller
et
al
muller
et
al
predilut
set
seri
defin
lowest
possibl
signific
titer
categor
sampl
posit
comparison
clinic
variabl
group
oneway
analysi
varianc
anova
kruskalw
test
use
continu
variabl
chisquar
fisher
exact
test
use
categor
variabl
sixweek
surviv
probabl
calcul
use
kaplanmei
method
cox
proport
hazard
model
logrank
test
use
examin
associ
seroconvers
statu
mortal
mer
patient
pneumonia
pvalu
consid
statist
signific
window
rstudio
boston
usa
use
statist
analys
seroconvers
statu
merscovinfect
patient
summar
tabl
none
group
patient
show
seroconvers
seroconvers
rate
gradual
increas
increas
diseas
sever
group
respect
p
seroconvers
observ
dpoi
dpoi
median
mostli
third
week
ill
seroconvert
patient
known
timelin
group
patient
show
slightli
delay
time
seroconvers
compar
group
patient
dpoi
median
respect
without
statist
signific
seroconvers
fourth
week
ill
exclus
observ
group
serolog
respons
seroconvert
patient
depict
accord
sever
group
interv
fig
serolog
respons
occur
third
week
ill
antibodi
respons
weaker
patient
mild
symptomat
patient
group
patient
pneumonia
group
group
patient
show
robust
increment
antibodi
titer
third
week
compar
week
median
od
ratio
elisa
igg
iga
increas
ifa
igm
prnt
increas
neg
respect
titer
significantli
increas
thereaft
comparison
median
valu
third
week
fourth
week
statist
signific
observ
meanwhil
group
patient
show
delay
continu
increment
antibodi
titer
third
week
median
valu
serolog
test
significantli
higher
fourth
week
compar
third
week
group
p
b
comparison
group
antibodi
titer
group
patient
third
week
numer
lower
group
although
elisa
igg
show
statist
signific
differ
p
antibodi
titer
group
patient
continu
increas
show
numer
higher
titer
compar
group
patient
fourth
week
without
statist
signific
detail
serolog
test
result
patient
present
accord
timelin
sever
group
supplementari
tabl
seroconvers
rate
low
mild
sever
group
group
group
outcom
analysi
perform
patient
pneumonia
group
deceas
patient
show
seroconvers
end
third
week
ill
surviv
patient
seroconvert
p
tabl
differ
also
could
discrimin
elisa
igg
od
ratio
cutoff
valu
p
elisa
iga
od
ratio
cutoff
valu
p
ifa
igm
respons
significantli
differ
survivor
nonsurvivor
intens
cutoff
valu
weakli
posit
p
kaplanmei
analysi
compar
seroconvert
patient
nonconvert
patient
third
week
ill
seroconvert
patient
show
significantli
higher
surviv
probabl
compar
patient
neg
seroconvers
fig
p
b
logrank
test
neg
seroconvers
pneumonia
patient
third
week
ill
show
hazard
ratio
ci
p
cox
proport
hazard
model
predict
mortal
sinc
previou
hospitalassoci
outbreak
mer
occur
endem
countri
primari
infect
flow
commun
hospit
detail
clinic
data
patient
hard
obtain
corman
et
al
howev
korean
mer
outbreak
first
outbreak
nonendem
countri
epidemiolog
link
entir
clinic
cours
patient
could
clearli
identifi
park
et
al
owe
detail
epidemiolog
clinic
inform
patient
could
find
differ
serolog
respons
depend
diseas
sever
outcom
although
differ
seroconvers
rate
depend
diseas
sever
infer
previou
serolog
investig
min
et
al
number
evalu
mer
patient
limit
neutral
test
perform
studi
robust
increment
elisa
igg
titer
increas
od
ratio
exclus
observ
among
patient
sever
pneumonia
mild
infect
exhibit
modest
increment
od
ratio
likewis
note
asymptomat
merscovinfect
case
show
serolog
respons
includ
prnt
within
month
seroconvers
rate
increas
diseas
sever
although
number
asymptomat
patient
limit
present
analysi
less
like
asymptomat
patient
experi
seroconvers
consid
even
group
patient
obviou
mersrel
symptom
show
low
seroconvers
rate
find
correl
anoth
serolog
studi
evalu
rrtpcrconfirm
mer
patient
choe
et
al
studi
antibodi
titer
patient
mild
ill
undetect
addit
contact
survey
merscov
could
detect
addit
rrtpcrneg
prntposit
merscov
infect
breakwel
et
al
buchholz
et
al
choi
et
al
find
impli
serolog
survey
detect
subclin
infect
among
asymptomat
individu
would
effect
serolog
respons
delay
group
patient
neg
seroconvers
third
week
ill
associ
fatal
outcom
among
patient
mer
pneumonia
hr
ci
p
delay
commenc
serolog
respons
sever
diseas
also
suggest
previou
report
park
et
al
park
et
al
although
seroconvers
time
statist
significantli
delay
group
patient
present
studi
delay
increment
igg
iga
igm
titer
third
week
demonstr
group
howev
delay
serolog
respons
group
could
use
predictor
respiratori
failur
respiratori
failur
progress
week
ill
dpoi
median
meanwhil
neg
seroconvers
mer
pneumonia
third
week
ill
associ
fatal
outcom
present
analysi
impair
serolog
respons
deceas
patient
also
note
paper
corman
et
al
insuffici
clinic
inform
especi
day
symptom
onset
hamper
detail
analysi
associ
timelin
corman
et
al
studi
could
obtain
exact
clinic
inform
includ
day
symptom
onset
figur
seroconvers
statu
third
week
ill
dpoi
serv
prognost
marker
anoth
import
point
merscovinfect
patient
present
analysi
die
later
previou
report
probabl
owe
antivir
therapi
aggress
critic
care
includ
extracorpor
membran
oxygen
ecmo
median
interv
symptom
onset
death
day
present
studi
much
longer
day
previou
report
zumla
et
al
although
rapidli
deterior
mer
case
would
die
third
week
ill
certainli
popul
benefit
prognosi
predict
serolog
respons
aggress
manag
includ
ecmo
consid
pneumonia
patient
without
seroconvers
third
week
ill
although
seroconvers
statu
confirm
neutral
test
readili
perform
worldwid
corman
et
al
tabl
seroconvers
statu
merscovinfect
patient
accord
diseas
sever
group
classif
diseas
sever
group
asymptomat
n
group
symptomat
n
group
pneumonia
n
group
resp
failur
n
present
analysi
seroconvers
statu
third
week
assess
elisa
igg
iga
similar
prnt
elisa
test
practic
use
predict
poor
prognosi
mer
pneumonia
field
patient
manag
retrospect
studi
serum
sampl
patient
could
collect
interv
howev
appli
strict
criteria
seroconvers
exclud
patient
followup
sampl
third
week
ill
indetermin
respons
previou
report
patient
popul
also
suggest
predict
factor
diseas
progress
use
clinic
variabl
within
day
symptom
onset
togeth
present
paper
factor
could
use
complementarili
manag
merscovinfect
patient
addit
although
identifi
seroconvers
statu
third
week
associ
fatal
outcom
mer
pneumonia
could
perform
multivari
analysi
due
limit
sampl
size
find
need
evalu
enough
patient
number
mer
pneumonia
conclus
serolog
investig
merscovinfect
patient
mild
case
show
low
seroconvers
rate
fatal
case
show
impair
serolog
respons
work
support
samsung
biomed
research
institut
sbri
grant
cd
report
fund
eu
grant
antigon
ga
prepar
ga
potenti
conflict
interest
relev
articl
report
